Security
Nuvectis Pharma, Inc. Common Stock · NVCT
NVCTNASDAQCommon stockCurrentCIK 1875558Updated Oct 6, 2026
NVCT price & chart
Loading TradingView…
NASDAQ:NVCT on TradingView ↗About the company
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
In the news
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors ↗
Recent filings
EFFECT filing
S-3 filing
Other Events
Items 8.01, 9.01
SCHEDULE 13G - filed by Soleus Private Equity Fund III, L.P. regarding Nuvectis Pharma, Inc.
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
4 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 35,587,000Source | 17,307,000Source | 22,376,000Source | 27,007,000Source | 18,298,000Source | 25,398,000Source | 30,148,000Source | 19,714,000Source | 31,709,000Source | 18,607,000Source | 19,185,000Source | 20,405,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 35,442,000Source | 17,169,000Source | 22,160,000Source | 26,793,000Source | 18,116,000Source | 25,130,000Source | 29,864,000Source | 19,464,000Source | 31,634,000Source | 18,533,000Source | 19,126,000Source | 19,993,000Source |
| Assets, CurrentUSD | 35,587,000Source | 17,307,000Source | 22,376,000Source | 27,007,000Source | 18,298,000Source | 25,398,000Source | 30,148,000Source | 19,714,000Source | 31,709,000Source | 18,607,000Source | 19,185,000Source | 20,405,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,577,000Source | 6,316,000Source | 13,294,000Source | 10,135,000Source | 5,770,000Source | 11,178,000Source | 9,194,000Source | 5,692,000Source | 13,296,000Source | 8,894,000Source | 6,984,000Source | 6,186,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 116,383,000Source | 77,988,000Source | 121,839,000Source | 101,783,000Source | 75,372,000Source | 119,957,000Source | 99,531,000Source | 72,438,000Source | 118,100,000Source | 82,958,000Source | 66,446,000Source | 46,204,000Source |
| Retained Earnings (Accumulated Deficit)USD | -92,373,000Source | -66,997,000Source | -112,757,000Source | -84,911,000Source | -62,844,000Source | -105,737,000Source | -78,577,000Source | -58,416,000Source | -99,687,000Source | -73,245,000Source | -54,245,000Source | -31,985,000Source |
| Stockholders' Equity Attributable to ParentUSD | 24,010,000Source | 10,991,000Source | 9,082,000Source | 16,872,000Source | 12,528,000Source | 14,220,000Source | 20,954,000Source | 14,022,000Source | 18,413,000Source | 9,713,000Source | 12,201,000Source | 14,219,000Source |
| Liabilities and EquityUSD | 35,587,000Source | 17,307,000Source | 22,376,000Source | 27,007,000Source | 18,298,000Source | 25,398,000Source | 30,148,000Source | 19,714,000Source | 31,709,000Source | 18,607,000Source | 19,185,000Source | 20,405,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,577,000Source | 6,316,000Source | 13,294,000Source | 10,135,000Source | 5,770,000Source | 11,178,000Source | 9,194,000Source | 5,692,000Source | 13,296,000Source | 8,894,000Source | 6,984,000Source | 6,186,000Source |
| Accounts Payable, CurrentUSD | 6,439,000Source | 2,261,000Source | 5,184,000Source | 4,977,000Source | 1,846,000Source | 4,695,000Source | 2,992,000Source | 1,759,000Source | 6,274,000Source | 2,498,000Source | 2,771,000Source | 2,910,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 65,000Source | 282,000Source | 92,000Source | 2,000Source | 310,000Source | 36,000Source | 865,000Source | 486,000Source | 115,000Source | 840,000Source | 415,000Source | 445,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -6,050,000Source | -5,332,000Source | -26,442,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,850,000Source | 1,368,000Source | 6,032,000Source | 4,858,000Source | 4,705,000Source | 1,707,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,579,000Source | 494,000Source | 3,776,000Source | -273,000Source | -139,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,511,000Source | -4,174,000Source | -16,009,000Source | -12,247,000Source | -15,954,000Source | -13,559,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | — | 0Source | 0Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,000Source | 15,505,000Source | 29,110,000Source | 11,654,000Source | 15,087,000Source | 27,810,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 35,442,000Source | 17,169,000Source | 22,160,000Source | 26,793,000Source | 25,130,000Source | 29,864,000Source | 31,634,000Source | 18,533,000Source | 19,126,000Source | 19,993,000Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,020,000Source | 1,540,000Source | 2,513,000Source | 2,982,000Source | 2,154,000Source | 1,888,000Source | 9,421,000Source | 6,929,000Source | 7,517,000Source | 6,007,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,462,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -26,442,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,891,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -28,871,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 12,036,000Source | 5,289,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -7,794,000Source | -4,359,000Source | -7,197,000Source | -6,595,000Source | -6,260,000Source | -5,568,000Source | -27,574,000Source | -19,847,000Source | -22,897,000Source | -19,234,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,462,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -26,442,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.44Source | -0.24Source | -0.3Source | -0.3Source | -0.26Source | -0.27Source | -1.32Source | -1.11Source | -1.43Source | -1.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.44Source | -0.24Source | -0.3Source | -0.3Source | -0.26Source | -0.27Source | -1.32Source | -1.11Source | -1.43Source | -1.51Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 22,719,057Source | 17,230,559Source | 23,475,989Source | 21,366,268Source | 23,414,475Source | 19,937,507Source | 21,812,716Source | 17,113,169Source | 15,556,655Source | 12,657,651Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 22,719,057Source | 17,230,559Source | 23,475,989Source | 21,366,268Source | 23,414,475Source | 19,937,507Source | 21,812,716Source | 17,113,169Source | 15,556,655Source | 12,657,651Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 2,020,000Source | 1,540,000Source | 2,513,000Source | 2,982,000Source | 2,154,000Source | 1,888,000Source | 9,421,000Source | 6,929,000Source | 7,517,000Source | 6,007,000Source |
| Labor and Related ExpenseUSD | — | — | — | — | — | — | — | — | 2,421,000Source | 2,091,000Source | 2,298,000Source | 1,756,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,891,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -28,871,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 461,000Source | 360,000Source | 548,000Source | 687,000Source |
| Research and Development ExpenseUSD | — | — | 5,774,000Source | 2,819,000Source | 4,684,000Source | 3,613,000Source | 4,106,000Source | 3,680,000Source | 18,153,000Source | 12,918,000Source | 15,380,000Source | 13,227,000Source |
Offerings
Registration 333-298495
Registration 333-293459
Filing attachments
tm2623146d1_ex4-6.htm · S-3 · 2026-08-21
Exhibit 4.6 NUVECTIS PHARMA, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [___] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Indenture Act Section Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), …
Read attachment ↗tm2622125d1_ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 tm2622125d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization. The Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, or…
Read attachment ↗tm2619346d1_ex99-1.htm · 8-K · 2026-06-30
EX-99.1 4 tm2619346d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Announces Proposed Public Offering of Common Stock FORT LEE, NJ, June 29, 2026 - Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offerin…
Read attachment ↗tm2619346d1_ex99-2.htm · 8-K · 2026-06-30
EX-99.2 5 tm2619346d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock FORT LEE, NJ, June 29, 2026 - Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common …
Read attachment ↗tm2618439d1_ex99-1.htm · 8-K · 2026-06-23
EX-99.1 2 tm2618439d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncolo…
Read attachment ↗tm2613389d1_ex99-1.htm · 8-K · 2026-05-05
EX-99.1 2 tm2613389d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategy May 5, 2026, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "…
Read attachment ↗